Skip to Content
E. Jason Abel, MD, FACS

Contact Dr. Abel


(608) 263-4563

UW Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705-2281

E. Jason Abel, MD, FACS

Assistant Professor
Department of Urology


  • BS, Zoology; BA, Molecular Biology, University of Texas at Austin, 1998
  • MD, The University of Texas at Houston Medical School, 2003
  • Residency, University of Utah Division of Urology, Salt Lake City, UT, 2008
  • Fellowship, Urologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2010

Dr. Abel specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.

Clinical Specialties

Dr. Abel is certified by the American Board of Urology. He performs open and laparoscopic surgery including surgery using the daVinci robot. Dr Abel’s philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.

Research Interests

Dr. Abel conducts clinical, translational, and basic research in urologic oncology. Clinical and translational interests include improving patient outcomes after complex urologic surgery, improving prognostic ability for patient decision making, and multidisciplinary care of kidney cancer.

Dr. Abel serves on the board of directors for the Society of Urologic Oncology (SUO) Clinical Trials Consortium.

  • Role of NFXB/HIF2A Axis in Renal Cell Carcinoma Progression
    Funding Agency: National Institutes of Health (NIH); National Cancer Institute (NCI) Career Development Award 1K08CA178168-01
    Principal Investigator(s): E. Jason Abel, MD, FACS
    More Information

Recent Publications
  • Lubner MG, Stabo N, Abel EJ, Del Rio AM, Pickhardt PJ. CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes. AJR Am J Roentgenol 2016 May 4; ():W1-W10.
    [PubMed ID: 27145377]
    More Information
  • Blute ML, Abel EJ. The evolving role of renal mass biopsy. Ann Transl Med 2016 Feb; 4(4):83.
    [PubMed ID: 27004230, PMCID: 4779777]
    More Information
  • Abel EJ. Re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol. In press. The Search for Accurate Diagnostic Rates in Renal Mass Biopsy. Eur. Urol. 2016 Jan 5.
    [PubMed ID: 26778464]
    More Information
  • Blute ML, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ. Extreme Obesity Does Not Predict Poor Cancer Outcomes Following Surgery for Renal Cell Cancer. BJU Int. 2015 Nov 21.
    [PubMed ID: 26589741]
    More Information
  • Abel EJ, Margulis V, Bauman TM, Karam JA, Christensen WP, Krabbe LM, Haddad A, Golla V, Wood CG. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. BJU Int. 2016 Jun; 117(6B):E87-94.
    [PubMed ID: 26305276]
    More Information
  • Blute ML, Drewry A, Abel EJ. Percutaneous biopsy for risk stratification of renal masses. Ther Adv Urol 2015 Oct; 7(5):265-74.
    [PubMed ID: 26425141, PMCID: 4549697]
    More Information
  • Cristescu M, Abel EJ, Wells S, Ziemlewicz TJ, Hedican SP, Lubner MG, Hinshaw JL, Brace CL, Lee FT. Percutaneous Microwave Ablation of Renal Angiomyolipomas. Cardiovasc Intervent Radiol 2016 Mar; 39(3):433-40.
    [PubMed ID: 26390876]
    More Information
  • Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol 2015 Aug; 12(8):435-44.
    [PubMed ID: 26171803]
    More Information
  • Blute ML, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J. Urol. 2015 Nov; 194(5):1214-9.
    [PubMed ID: 26173101]
    More Information
  • Potretzke AM, Wong KS, Shi F, Christensen W, Downs TM, Abel EJ. Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann 2015 Jul-Sep; 7(3):355-60.
    [PubMed ID: 26229325, PMCID: 4518374]
    More Information Copyright © 2016 The Board of Regents of the University of Wisconsin System